pharma news today obesity drugs glp-1 today health october 2025 Outlook for obesity in 2025: more GLP-1 drugs transform obesity care,

Pocai A

Conclusion The GLP-1 revolution is one of those rare moments in medicine when a class of drugs reshapes clinical expectations

Individuals with minimal weight to lose (BMI under 27 kg/m without comorbidities) do not meet clinical criteria for pharmacological weight loss treatment

In an exploratory analysis of REWIND, the hazard of substantive cognitive impairment was reduced by 14% in the dulaglutide group [62]

doi: 10.1007/s40256-024-00706-9 19 KosiborodMNAbildstrmSZBorlaugBAButlerJRasmussenSDaviesMet al

Patients tolerating once-daily GLP-1 receptor agonist therapy at the maximal therapeutic dose should start a once-weekly GLP-1 receptor agonist the day after their last dose of once-daily medication